康柏西普辅助玻璃体切割治疗增生型糖尿病视网膜病变的疗效分析  

Analysis of the efficacy of conbercept assisted vitrectomy in the treatment of proliferative diabetic retinopathy

作　　者：雷建平 LEI Jianping(Department of Ophthalmology,Pingmei Shenma Group General Hospital,Pingdingshan 467000,China)

机构地区：[1]平煤神马集团总医院眼科,平顶山467000

出　　处：《上海医药》2022年第13期33-35,91,共4页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:研究术前玻璃体腔注射康柏西普辅助23G玻璃体切割治疗增殖期糖尿病性视网膜病变(PDR)的临床效果。方法:回顾性分析PDR患者资料,分为单纯手术组和药物联合手术组各20例。两组均行23G玻璃体切割手术,药物联合手术组于术前采用玻璃体腔注射康柏西普。观察两组手术持续时间、术中电凝的使用和术后最佳矫正视力(BCVA)变化情况。结果:与单纯手术组相比,药物联合手术组平均手术时间、术中电凝止血使用率更低;术后平均BCVA更高(均P<0.05)。结论:玻璃体腔注射康柏西普辅助23G玻璃体切割治疗PDR可以缩短手术时间、减少术中出血,提高患者视力。Objective:To study the clinical efficacy of 23G vitrectomy combined with preoperative intravitreal injection of conbercept in the treatment of proliferative diabetic retinopathy(PDR).Methods:Medical records from patients with PDR were retrospectively analyzed and they were divided into a surgery-only group and a drug-combined surgery group with 20 cases(eyes)each.Both groups were treated with the 23G vitrectomy,while conbercept was injected into the vitreous cavity in the drug-combined group before the surgery.The duration of the surgery,the use of electrocoagulation during vitrectomy and the best-corrected visual acuity(BCVA)after the surgery were observed.Results:The mean operation time and the use rate of electrocoagulation for hemostasis were lower and the postoperative BCVA was higher in the drug-combined group than the surgery-only group(all P<0.05).Conclusion:Intravitreal injection of conbercept combined with 23G vitrectomy in the treatment of PDR can shorten the operation time,reduce intraoperative bleeding and improve visual acuity.

关 键 词：康柏西普 增生型糖尿病性视网膜病变 23G 玻璃体切割术 

分 类 号：R988.1[医药卫生—药品] R774.13[医药卫生—药学]